Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024)
Alumis (ALMS) reported Preferred Stock Liabilities of $639.2 million for Q2 2024, up 86.28% year-over-year from $343.2 million in Q3 2023, and up 28.99% quarter-over-quarter from $495.6 million in Q1 2024.
Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Alumis (ALMS) has 2 years of Preferred Stock Liabilities data on file, last reported at $639.2 million in Q2 2024.
- Preferred Stock Liabilities for Q2 2024 came in at $639.2 million, up 86.28% year-over-year; the trailing twelve-month figure through Jun 2024 was $639.2 million (up 86.28% YoY), and the FY2023 annual result was $375.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities improved to $639.2 million in Q2 2024 per ALMS's latest filing, from $495.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $639.2 million in Q2 2024 and troughed at $343.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 639.24 Mn |
| Mar 31, 2024 | 495.58 Mn |
| Dec 31, 2023 | 375.37 Mn |
| Sep 30, 2023 | 343.15 Mn |
| Jun 30, 2023 | 343.15 Mn |